A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease

You may be eligible if

• Adult or pediatric patients with IBD (CD or UC) currently receiving MTX as part of their clinical care.
• Patients must be receiving weekly MTX at a dose between 7.5 and 40 mg/m2.
• Weight \>= 12 kg.
• Normal serum creatinine.